Fig. 2

Investigator-assessed PFS by a prognostic factors and b prior lines of therapy. BR bendamustine and rituximab, CI confidence interval, EVT event, IGHV immunoglobulin heavy-chain variable, HR hazard ratio, LDi longest diameter, NE not evaluable, PFS progression-free survival